Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Cancer Cytopathol. 2021 Nov 30;130(4):284–293. doi: 10.1002/cncy.22537

TABLE 3.

Comparison of Different Molecular Platforms

ThyroSeq (n = 66) ThyGenX/ThyraMIR (n = 52) ThyroSure (n = 9)
RAS Alone RAS With Others RAS Alone RAS With Others RAS Alone RAS With Others
Histology, No. n = 35 n = 31 n = 6
 Malignant 4 3 2 10 1 1
 Benign 19 9 9 10 3 1
ROM (RAS alone), % 17 18 25
ROM (RAS with others), % 25 50 a
ROM (overall), % 20 39 33

Abbreviation: ROM, risk of malignancy.

a

The number was too low for an appropriate calculation.